Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
AbraSilver Intersects 75 Meters Grading 2.44 g/t Gold at Diablillos Project

AbraSilver Intersects 75 Meters Grading 2.44 g/t Gold at Diablillos Project

BitgetBitget2026/11/09 12:34
  • AbraSilver intersected 75 meters grading 2.44 g/t gold and 106 g/t silver within the planned Oculto pit at Argentina's Diablillos project.
  • At Oculto East, drilling intersected 253 meters grading 0.54 g/t gold, extending oxide mineralization largely below the current pit design.
  • The results will feed into an updated mineral resource estimate expected in the second quarter of 2027.
  • Phase VI drilling remains on track for completion by year-end 2026, with three rigs operating.
  • A final construction decision remains scheduled for the second quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abrasilver Resource Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611090730NEWSFILECNPR____20261109_322952_1) on November 09, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12